{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Dittmar RL"],"funding":["The Cancer Prevention Institute of Texas","NIEHS NIH HHS","NIEHS","NCI NIH HHS","National Institutes of Health Translational Genomics and Precision Medicine in Cancer T32 Training Program","Cancer Prevention Research Institute of Texas","NIH","NIH NCI"],"pagination":["729-740"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8818322"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(7)"],"pubmed_abstract":["Early detection of pancreatic ductal adenocarcinoma (PDAC) is key to improving patient outcomes; however, PDAC is usually diagnosed late. Therefore, blood-based minimally invasive biomarker assays for limited volume clinical samples are urgently needed. A novel miRNA profiling platform (Abcam Fireplex-Oncology Panel) was used to investigate the feasibility of developing early detection miRNA biomarkers with 20 μL plasma from a training set (58 stage II PDAC cases and 30 controls) and two validation sets (34 stage II PDAC cases and 25 controls; 44 stage II PDAC cases and 18 controls). miR-34a-5p [AUC = 0.77; 95% confidence interval (CI), 0.66-0.87], miR-130a-3p (AUC = 0.74; 95% CI, 0.63-0.84), and miR-222-3p (AUC = 0.70; 95% CI, 0.58-0.81) were identified as significantly differentially abu"],"journal":["Cancer prevention research (Philadelphia, Pa.)"],"pubmed_title":["Plasma miRNA Biomarkers in Limited Volume Samples for Detection of Early-stage Pancreatic Cancer."],"pmcid":["PMC8818322"],"funding_grant_id":["U01 CA200466","U01 CA252965","1P42ES0327725","RP170005","U01CA200468","CA125123","U01 CA196403","U01 CA200468","T32 CA217789","P30 ES030285","5T32CA217789-03","P30 CA125123","U01CA196403","U01 CA214263","P50CA221707","P50 CA221707","RP180392","1 U01 CA214263","1P30ES030285"],"pubmed_authors":["Tai MC","Longton G","DeCapite C","Coarfa C","Rajapakshe K","Liu S","Paris PL","Sen S","Huang Y","Kirkwood KS","Maitra A","Hurd MW","Brand RE","Dittmar RL","Killary AM"],"additional_accession":[]},"is_claimable":false,"name":"Plasma miRNA Biomarkers in Limited Volume Samples for Detection of Early-stage Pancreatic Cancer.","description":"Early detection of pancreatic ductal adenocarcinoma (PDAC) is key to improving patient outcomes; however, PDAC is usually diagnosed late. Therefore, blood-based minimally invasive biomarker assays for limited volume clinical samples are urgently needed. A novel miRNA profiling platform (Abcam Fireplex-Oncology Panel) was used to investigate the feasibility of developing early detection miRNA biomarkers with 20 μL plasma from a training set (58 stage II PDAC cases and 30 controls) and two validation sets (34 stage II PDAC cases and 25 controls; 44 stage II PDAC cases and 18 controls). miR-34a-5p [AUC = 0.77; 95% confidence interval (CI), 0.66-0.87], miR-130a-3p (AUC = 0.74; 95% CI, 0.63-0.84), and miR-222-3p (AUC = 0.70; 95% CI, 0.58-0.81) were identified as significantly differentially abu","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jul","modification":"2026-05-31T20:54:43.615Z","creation":"2025-04-06T11:13:34.788Z"},"accession":"S-EPMC8818322","cross_references":{"pubmed":["33893071"],"doi":["10.1158/1940-6207.capr-20-0303","10.1158/1940-6207.CAPR-20-0303"]}}